切换至 "中华医学电子期刊资源库"

中华肝脏外科手术学电子杂志 ›› 2017, Vol. 06 ›› Issue (04): 316 -319. doi: 10.3877/cma.j.issn.2095-3232.2017.04.018

所属专题: 经典病例 文献

临床研究

101例原发性胆汁性肝硬化患者的临床特征回顾性分析
毕建斌1, 李泽宇1, 顾静娴1, 苗润晨1, 张佳1, 杜肇清1, 曲凯1, 刘昌1,()   
  1. 1. 710061 西安交通大学第一附属医院肝胆外科
  • 收稿日期:2017-04-01 出版日期:2017-08-10
  • 通信作者: 刘昌
  • 基金资助:
    国家自然科学基金(81601672)

Clinical characteristics of primary biliary cirrhosis: a retrospective analysis of 101 cases

Jianbin Bi1, Zeyu Li1, Jingxian Gu1, Runchen Miao1, Jia Zhang1, Zhaoqing Du1, Kai Qu1, Chang Liu1,()   

  1. 1. Department of Hepatobiliary Surgery, the First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710061, China
  • Received:2017-04-01 Published:2017-08-10
  • Corresponding author: Chang Liu
  • About author:
    Corresponding author:Liu Chang, Email:
目的

探讨原发性胆汁性肝硬化(PBC)患者的临床特征,为其诊治提供参考依据。

方法

回顾性分析2005年10月至2016年11月西安交通大学第一附属医院收治的101例PBC患者临床资料。其中男7例,女94例;年龄17~80岁,中位年龄59岁。患者均签署知情同意书,符合医学伦理学规定。总结患者的年龄、性别、症状、体征等一般资料,分析入院后血常规、肝肾功能、凝血功能、自身抗体等诊断指标,以及治疗方式的选择。

结果

PBC患者中女性占93.1%(94/101)。乏力、黄疸、呕血和黑便、皮肤瘙痒发生率分别占52.5%(53/101)、33.7%(34/101)、14.9%(15/101)、12.9%(13/101)。脾大、腹腔积液、肝病面容、蜘蛛痣体征分别占73.3%(74/101)、48.5%(49/101)、33.7%(34/101)、5.9%(6/101)。患者常出现三系细胞减少,血清ALT、AST、ALP、GGT、TB、DB异常和凝血功能障碍,其中DB异常发生率97.0%(98/101)。抗线粒体抗体(AMA)、抗核抗体(ANA)阳性率分别高达81.2%(82/101)、79.2%(80/101)。熊去氧胆酸等药物治疗占69.3%(70/101),肝移植占16.8%(17/101),其余对症治疗措施占13.9%(14/101)。

结论

掌握PBC的临床特征,有助于其早期诊断及治疗。

Objective

To investigate the clinical characteristics of patients with primary biliary cirrhosis (PBC) and provide reference for the diagnosis and treatment of PBC.

Methods

Clinical data of 101 patients with PBC who were admitted to the First Affiliated Hospital of Xi'an Jiaotong University between October 2005 and November 2016 were retrospectively analyzed. Among them, 7 cases were males and 94 were females, aged 17-80 years old with a median age of 59 years old. The informed consents of all patients were obtained and the local ethical committee approval was received. General data such as age, gender, symptoms and physical signs were summarized. Diagnostic indicators after admission such as routine blood test, liver and renal function, coagulation function and autoantibody, and selection of therapy were analyzed.

Results

The percentage of females among PBC patients was 93.1%(94/101). The incidence of asthenia, jaundice, hematemesis and melena, cutaneous pruritus was respectively 52.5%(53/101), 33.7%(34/101), 14.9%(15/101), 12.9%(13/101). The incidence of splenomegaly, peritoneal effusion, hepatic face and nevus araneus was respectively 73.3%(74/101), 48.5%(49/101), 33.7%(34/101) and 5.9%(6/101). Pancytopenia, abnormal levels of serum ALT, AST, ALP, GGT, TB and DB, and coagulation dysfunction were constantly observed. The incidence of DB abnormality was 97.0% (98/101). The positive rate of anti-mitochondrial antibody (AMA) and antinuclear antibody (ANA) was respectively up to 81.2%(82/101) and 79.2%(80/101). Among all the treatment, drug therapy such as ursodesoxycholic acid accounted for 69.3%(70/101), liver transplantation accounted for 16.8%(17/101) and other symptomatic therapies accounted for 13.9%(14/101).

Conclusions

Mastering the clinical characteristics of PBC patients contributes to early diagnosis and treatment of PBC.

表1 101例PBC患者的自身抗体谱筛查结果
[1]
Xie YQ, Ma HD, Lian ZX. Epigenetics and primary biliary cirrhosis: a comprehensive review and implications for autoimmunity[J]. Clin Rev Allerg Immunol, 2016, 50(3):390-403.
[2]
Boonstra K, Beuers U, Ponsioen CY. Epidemiology of primary sclerosing cholangitis and primary biliary cirrhosis: a systematic review[J]. J Hepatol, 2012, 56(5):1181-1188.
[3]
Carey EJ, Ali AH, Lindor KD. Primary biliary cirrhosis[J]. Lancet, 2015, 386(10003):1565-1575.
[4]
李彩虹,白石山.原发性胆汁性肝硬化发病机制和治疗的研究探析[J].内蒙古医学杂志,2014,46(5):564-566.
[5]
张攀,张莉,郭长吉,等.原发性胆汁性肝硬化的病因学研究进展[J].胃肠病学和肝病学杂志,2015,24(2):229-233.
[6]
Griffiths L, Dyson JK, Jones DE. The new epidemiology of primary biliary cirrhosis[J]. Semin Liver Dis, 2014, 34(3):318-328.
[7]
王卫彬,朱幼芙.原发性胆汁性肝硬化病理机制浅谈[J].临床肝胆病杂志,2013,29(11):805-809.
[8]
邱春婷,王艳荣,卢建华,等.原发性胆汁性肝硬化患者临床与病理学特征分析[J].山东医药,2014,54(36):56-59.
[9]
Rudic JS, Poropat G, Krstic MN, et al. Ursodeoxycholic acid for primary biliary cirrhosis[J]. Cochrane Database Syst Rev, 2012(12):CD000551.
[10]
毛丽.熊去氧胆酸治疗原发性胆汁性肝硬化的效果分析[J].医学前沿,2014,2(5):20-21.
[11]
Zhang Y, Li S, He L, et al. Combination therapy of fenofibrate and ursodeoxycholic acid in patients with primary biliary cirrhosis who respond incompletely to UDCA monotherapy: a meta-analysis[J]. Drug Des Devel Ther, 2015(9):2757-2766.
[12]
Lindor KD, Gershwin ME, Poupon R, et al. Primary biliary cirrhosis[J]. Hepatology, 2009, 50(1):291-308.
[13]
傅斌生,汪根树,李华,等.肝移植治疗原发性胆汁性肝硬化临床疗效分析[J/CD].中华肝脏外科手术学电子杂志,2012,1(2):85-89.
[14]
何方平,陈兰.原发性胆汁性肝硬化的流行病学及自然病程研究进展[J].实用肝脏病杂志,2013,16(2):97-98.
[15]
Nakamura M. Clinical significance of autoantibodies in primary biliary cirrhosis[J]. Semin Liver Dis, 2014, 34(3):334-340.
[16]
姚定康.462例原发性胆汁性肝硬化临床特点分析[J].实用肝脏病杂志,2013,16(2):105-107.
[17]
罗莉丽,周璐,张洁,等.血清自身抗体在诊断抗线粒体抗体阴性的原发性胆汁性肝硬化中的价值[J].中华消化杂志,2015,35(2):86-89.
[18]
李勇,王金湖,张悦梅,等.抗线粒体抗体在原发性胆汁性肝硬化筛查中的应用[J].临床检验杂志,2016,34(1):73-75.
[19]
Poupon R. Ursodeoxycholic acid and bile-acid mimetics as therapeutic agents for cholestatic liver diseases: an overview of their mechanisms of action[J]. Clin Res Hepatol Gastroenterol, 2012, 36 (Suppl 1):S3-12.
[20]
樊雪强,王彩生,刘金涛,等.熊去氧胆酸在原发性胆汁性肝硬化临床治疗中的进展[J].中国医药导报,2016,13(24):58-61.
[21]
秦华,白石山.原发性胆汁性肝硬化的治疗进展[J].临床肝胆病杂志,2013,29(9):719-721.
[22]
周双男,张宁,张敏,等.肝移植治疗原发性胆汁性肝硬化临床分析[J].中华内科杂志,2015,54(12):1023-1027.
[1] 曹婉悦, 陆晶, 徐军明. 芳香烃受体的激活在大鼠肝移植免疫应答中的作用及机制研究[J]. 中华普通外科学文献(电子版), 2022, 16(03): 177-182.
[2] 杨占宇, 卢倩. 体外肝切除自体肝移植治疗肝细胞癌[J]. 中华普通外科学文献(电子版), 2022, 16(03): 182-182.
[3] 赵渊宇, 毛家玺, 傅宏, 刘聪, 郭闻渊, 滕飞. 肝移植相关性应激性心肌病临床特征和诊治[J]. 中华肝脏外科手术学电子杂志, 2022, 11(03): 278-282.
[4] 顾世杰, 马麟, 陈秋源, 崔瑞文, 赖柏聪, 石小红, 孟凡航, 易述红, 曹荣华. 徒手-机器联合复苏在脑死亡供者心脏骤停后器官维护中的作用[J]. 中华肝脏外科手术学电子杂志, 2022, 11(03): 283-287.
[5] 赵帅, 王健, 韩冰, 张亦弛, 丁瀚, 蔡浩, 顾劲扬. 肝移植治疗儿童Abernethy畸形合并肝肺综合征一例并文献复习[J]. 中华肝脏外科手术学电子杂志, 2022, 11(03): 288-293.
[6] 江哲龙, 魏志鸿, 杜俊杰, 江艺, 吕立志, 杨芳. FOXC2对肝癌肝移植患者预后的影响[J]. 中华肝脏外科手术学电子杂志, 2022, 11(03): 309-314.
[7] 阙清扬, 余炯杰, 凌孙彬, 徐骁. 免疫治疗在肝癌肝移植降期治疗中的应用及前景[J]. 中华肝脏外科手术学电子杂志, 2022, 11(03): 221-224.
[8] 蒋超, 吕国悦, 吴广振, 吴庆远, 王蒙. 胆道闭锁儿童肝移植治疗现状与进展[J]. 中华肝脏外科手术学电子杂志, 2022, 11(03): 235-238.
[9] 孙克彦, 毛家玺, 刘业, 刘聪, 郭闻渊, 张磊, 滕飞. HBV相关性慢加急性肝衰竭等待肝移植患者血浆置换疗效影响因素[J]. 中华肝脏外科手术学电子杂志, 2022, 11(03): 252-257.
[10] 刘剑戎, 谢芝芝, 黎利娟, 吕海金, 安玉玲, 易小猛, 魏绪霞, 席云, 易慧敏, 熊天威. 器官保存液病原体与肝移植受者感染关系分析[J]. 中华肝脏外科手术学电子杂志, 2022, 11(03): 273-277.
[11] 中华医学会外科学分会外科手术学学组, 中华医学会外科学分会移植学组. 劈离式肝移植供体及供肝评估专家共识[J]. 中华肝脏外科手术学电子杂志, 2022, 11(02): 133-138.
[12] 李晓斌, 冯啸, 谢云亮, 杨洲, 杨卿, 傅斌生, 易述红, 杨扬, 陈规划. Kasai手术对胆道闭锁患儿肝移植疗效的影响[J]. 中华肝脏外科手术学电子杂志, 2022, 11(02): 149-153.
[13] 李嘉伟, 庄雅峰, 王明, 柯瑞盛, 江艺, 蔡秋程. 肝移植术后长期存活患者生存情况单中心分析[J]. 中华肝脏外科手术学电子杂志, 2022, 11(02): 182-187.
[14] 肖慜, 顾杨军, 林鑫, 庄莉, 李启勇. T管支撑与内镜综合治疗肝移植术后胆管坏死合并胆管结石一例[J]. 中华肝脏外科手术学电子杂志, 2022, 11(02): 206-208.
[15] 刘华泽, 黄健峰, 杨静雯, 顾劲扬. 肝移植术后急性肾损伤诊治进展[J]. 中华肝脏外科手术学电子杂志, 2022, 11(02): 212-214.
阅读次数
全文


摘要